Woori IO

OSR Holdings continues to develop pipelines in varied therapeutic areas. Vaximm is developing a versatile proprietary platform directing cytotoxic T-cells against a wide range of epitopes with p.o. dosing. VXM01 is a clinical stage VEGFR-2 inhibitor with pre-clinically proven anti-angiogenic activity, and encouraging Phase 1/2 safety profile in pancreatic cancer and GBM. Development expansion into other oncology and non-oncology indications is currently being investigated.

Meanwhile the Darnatein platform is a synthetic biology platform employing AI to generate “hybrid” versions of endogenous proteins with superior activity and excellent safety profile. Lead asset DRT-101 is engineered to function as BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical need and potential as a DMOAD. DRT-101 is targeting 2026 IND submission in Korea and subsequent submissions to other regulatory agencies to follow (EU, US).

OSR Holdings continues to develop pipelines in varied therapeutic areas. Vaximm is developing a versatile proprietary platform directing cytotoxic T-cells against a wide

range of epitopes with p.o. dosing. VXM01 is a clinical stage VEGFR-2 inhibitor with pre-clinically proven anti-angiogenic activity, and encouraging Phase 1/2 safety profile in pancreatic

cancer and GBM. Development expansion into other oncology and non-oncology indications is currently being investigated.

Meanwhile the Darnatein platform is a synthetic biology platform employing AI to generate “hybrid” versions of endogenous proteins with superior activity and excellent safety profile. Lead asset DRT-101 is engineered to function as BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical need and potential as a DMOAD. DRT-101 is targeting 2026 IND submission in Korea and subsequent submissions to other regulatory agencies to follow (EU, US). At the same time, DRT-102 has applications in bone fusion, and is already in clinical studies in South Korea. DRT-102 is already shown to have an excellent safety profile with efficacy data (75% bone fusion rate).